King Luther Capital Management Corp Buys 6,696 Shares of Abbott Laboratories $ABT

King Luther Capital Management Corp raised its stake in Abbott Laboratories (NYSE:ABT) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,435,459 shares of the healthcare product maker’s stock after acquiring an additional 6,696 shares during the period. King Luther Capital Management Corp’s holdings in Abbott Laboratories were worth $192,265,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ABT. Carr Financial Group Corp boosted its position in Abbott Laboratories by 2.0% in the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares during the last quarter. Tortoise Investment Management LLC raised its holdings in Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after acquiring an additional 77 shares during the period. Gemmer Asset Management LLC lifted its position in shares of Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after acquiring an additional 78 shares in the last quarter. Bridgewater Advisors Inc. boosted its stake in shares of Abbott Laboratories by 0.6% in the second quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock worth $1,607,000 after acquiring an additional 79 shares during the period. Finally, Nia Impact Advisors LLC grew its position in shares of Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after purchasing an additional 79 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABT. Evercore dropped their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. The Goldman Sachs Group decreased their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Sanford C. Bernstein reduced their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Oppenheimer decreased their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Stock Up 0.9%

Shares of NYSE ABT opened at $113.32 on Thursday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The firm’s 50-day moving average price is $118.94 and its 200-day moving average price is $126.10. The stock has a market capitalization of $197.05 billion, a price-to-earnings ratio of 30.46, a P/E/G ratio of 1.79 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Thursday, January 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.